Traders should monitor the tender offer expiration on August 26, 2026, and any HSR clearance updates. The acquisition is a strategic pipeline expansion for argenx, but the lack of a disclosed total deal value limits precise financial impact assessment. Watch for any competing bids or regulatory delays.
Drug in focus
ARGX drug pipeline →FB102
● Neutral Named in this press release- Impact
- Phase
- Phase 1b (proof-of-concept completed); Phase 2 (celiac disease) ongoing
- Time to market
- Likely 3-5+ years from 2026, pending Phase 2 celiac readout and Phase 3 development. FB102 is currently in Phase 1b/2-stage development with argenx's resources expected to accelerate the pipeline post-acquisition.
- Next catalyst
- None dated
What to watchFor ARGX investors, FB102 is a bolt-on pipeline asset that adds long-term optionality but is not a near-term binary driver given argenx's ~$53B market cap and $1.5B H1 2026 VYVGART revenue. Watch for Phase 2 celiac disease readout (H2 2026) and the deal closing (expected by late Q3). For FBRX holders, the stock trades near the $77 offer price, the arbitrage spread hinges on antitrust clearance and deal timing.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $875.30entry
- T+1 · 3mo ago −1.17%α −1.78% · $865.04
- T+5 · 3mo ago −2.10%α −3.31% · $856.94
- T+20 · 3mo ago +20.35%α +19.75% · $1,053.46
- T+60 · 18d ago +2.01%α +3.68% · $892.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, a deal valued at an undisclosed total amount. The offer, supported by Forte's Board, is subject to a minimum tender condition of more than 50% of shares and HSR clearance, with no financing condition. This acquisition adds Forte's anti-CD122 antibody candidate FB102 to argenx's immunology pipeline, representing a strategic expansion into a new autoimmune target.
Key Facts
- argenx commenced a tender offer for Forte Biosciences at $77.00 per share in cash.
- The offer is subject to a minimum condition of more than 50% of shares tendered and HSR clearance.
- Forte's Board recommends the offer; no stockholder vote is required under Delaware law.
- The acquisition adds FB102, an anti-CD122 antibody, to argenx's pipeline.
- Offer expires at 11:59 p.m. ET on August 26, 2026, unless extended.
Financial Impact
$77.00 per share in cash; total deal value not disclosed in the press release.
Risk Factors
- Risk that the minimum tender condition or HSR clearance is not met, delaying or terminating the deal.
- Integration risk and uncertainty around FB102's clinical development and commercial potential.
- Potential stockholder litigation or competing acquisition proposals for Forte.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340172 |
Track record
23 reports on ARGX
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $960.04 +7.29% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $960.04 +6.93% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $960.04 +9.62% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $960.04 +16.28% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $960.04 +17.27% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $960.04 −1.09% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $960.04 −2.44% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers